Spruce Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Spruce Biosciences Common
SPRB Stock  USD 81.90  2.34  2.78%   
Spruce Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Spruce Biosciences' valuation are provided below:
Gross Profit
-36.2 M
Market Capitalization
85.5 M
Enterprise Value Revenue
112.3993
Revenue
697 K
Earnings Share
(84.32)
We have found one hundred twenty available fundamental trend indicators for Spruce Biosciences Common, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Spruce Biosciences Common current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of January 30, 2026, Market Cap is expected to decline to about 120.2 M. In addition to that, Enterprise Value is expected to decline to about 20 M

Spruce Biosciences Total Revenue

5.93 Million

Check Spruce Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spruce Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 3.8 M, Depreciation And Amortization of 48.2 K or Interest Expense of 305.3 K, as well as many indicators such as Price To Sales Ratio of 7.89, Dividend Yield of 0.0 or PTB Ratio of 0.55. Spruce financial statements analysis is a perfect complement when working with Spruce Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Spruce Stock
Check out the analysis of Spruce Biosciences Correlation against competitors.

Spruce Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets83.9 M52 M41.6 M
Slightly volatile
Other Current Liabilities7.3 M13.9 M4.2 M
Slightly volatile
Total Current Liabilities12.2 M17.5 M7.6 M
Slightly volatile
Accounts Payable1.9 M1.2 M2.2 M
Pretty Stable
Cash57.8 M44.6 M29.6 M
Slightly volatile
Non Current Assets Total1.1 M1.2 M2.6 M
Pretty Stable
Non Currrent Assets Other75.4 K79.3 K3.4 M
Pretty Stable
Other Assets1.091.1571.4 K
Pretty Stable
Cash And Short Term Investments73.6 M44.6 M36.4 M
Slightly volatile
Common Stock Total Equity3.6 K3.5 K1.7 K
Slightly volatile
Common Stock Shares Outstanding543.7 K616.9 K281.1 K
Slightly volatile
Liabilities And Stockholders Equity83.9 M52 M41.6 M
Slightly volatile
Non Current Liabilities Total976.4 K1 M13.6 M
Slightly volatile
Other Current Assets3.7 M6.3 M2.3 M
Slightly volatile
Total Liabilities16.9 M14.7 M21.2 M
Slightly volatile
Total Current Assets77.3 M50.8 M38.7 M
Slightly volatile
Capital Stock2.8 K4.6 K2 K
Slightly volatile
Net Working Capital65 M33.3 M31.1 M
Slightly volatile
Common Stock2.8 K4.6 K2 K
Slightly volatile
Short and Long Term Debt Total4.1 M2.5 M4.6 M
Very volatile
Other Liabilities102.3 K185.2 K68.3 K
Slightly volatile
Long Term Debt106 K111.6 K2.6 M
Slightly volatile
Short and Long Term Debt1.4 M1.5 M1.4 M
Slightly volatile
Non Current Liabilities Other394.4 K324.3 K179.4 K
Slightly volatile
Short Term Debt1.8 M2.2 M1.5 M
Slightly volatile
Property Plant And Equipment Net1.1 M840.6 K1.6 M
Slightly volatile
Long Term Debt Total2.9 M3.8 M2.4 M
Slightly volatile
Capital Surpluse235.7 M251.1 M216.1 M
Slightly volatile
Capital Lease Obligations1.1 M917.1 K1.5 M
Slightly volatile
Property Plant And Equipment Gross1.1 M840.6 K1.6 M
Slightly volatile
Property Plant Equipment1.3 M1.3 M1.7 M
Slightly volatile
Current Deferred Revenue3.9 M4.4 M4.8 M
Slightly volatile

Spruce Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization48.2 K52.9 K24.5 K
Slightly volatile
Selling General Administrative9.5 M16.8 M5.8 M
Slightly volatile
Other Operating Expenses41.6 M70.2 M26.9 M
Slightly volatile
Research Development32.2 M53.4 M21 M
Slightly volatile
Cost Of Revenue59.7 M56.8 M12.7 M
Slightly volatile
Total Operating Expenses41.6 M70.2 M26.9 M
Slightly volatile
Reconciled Depreciation49.5 K52.9 K25 K
Slightly volatile
Non Operating Income Net Other947.6 K1.8 M646.5 K
Slightly volatile
Interest Income2.6 M3.9 M1 M
Slightly volatile
Selling And Marketing Expenses56 K63 K68.8 K
Slightly volatile

Spruce Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation6.5 M6.2 M1.9 M
Slightly volatile
Begin Period Cash Flow116.3 M110.8 M39.4 M
Slightly volatile
Depreciation104 K52.9 K48.6 K
Slightly volatile
End Period Cash Flow57.9 M44.6 M29.6 M
Slightly volatile
Change To Netincome4.4 M4.2 M1.5 M
Slightly volatile
Dividends Paid236.8 K152.1 K351.3 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.893.969.8795
Slightly volatile
Stock Based Compensation To Revenue0.620.980.5355
Slightly volatile
Capex To Depreciation0.110.120.4238
Very volatile
Payables Turnover0.0060.00580.0032
Slightly volatile
Sales General And Administrative To Revenue1.72.681.4656
Slightly volatile
Research And Ddevelopement To Revenue5.748.515.4292
Slightly volatile
Capex To Revenue6.0E-46.0E-47.0E-4
Slightly volatile
Cash Per Share15983.08171
Slightly volatile
Days Payables Outstanding45.7 K51.4 K56.1 K
Slightly volatile
Income Quality0.991.210.9071
Slightly volatile
Current Ratio3.173.333.7672
Slightly volatile
Capex Per Share0.01530.01610.0245
Pretty Stable
Revenue Per Share16.1210.5318.7023
Slightly volatile
Interest Debt Per Share10.476.598.4871
Slightly volatile
Debt To Assets0.06680.07030.5812
Slightly volatile
Days Of Payables Outstanding45.7 K51.4 K56.1 K
Slightly volatile
Ebt Per Ebit1.081.090.9952
Slightly volatile
Quick Ratio3.173.333.7672
Slightly volatile
Net Income Per E B T0.810.910.9936
Slightly volatile
Cash Ratio4.992.923.0509
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0152
Slightly volatile
Fixed Asset Turnover7.596.058.1469
Slightly volatile
Debt Ratio0.06680.07030.5812
Slightly volatile
Price Sales Ratio7.893.969.8795
Slightly volatile
Asset Turnover0.080.09780.0968
Pretty Stable

Spruce Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap120.2 M126.5 M164.1 M
Pretty Stable
Enterprise Value20 M21 M127 M
Pretty Stable

Spruce Fundamental Market Drivers

Spruce Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Spruce Biosciences Financial Statements

Spruce Biosciences stakeholders use historical fundamental indicators, such as Spruce Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Spruce Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Spruce Biosciences' assets and liabilities are reflected in the revenues and expenses on Spruce Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Spruce Biosciences Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.4 M3.9 M
Total Revenue5.6 M5.9 M
Cost Of Revenue56.8 M59.7 M
Stock Based Compensation To Revenue 0.98  0.62 
Sales General And Administrative To Revenue 2.68  1.70 
Research And Ddevelopement To Revenue 8.51  5.74 
Revenue Per Share 10.53  16.12 
Ebit Per Revenue(13.15)(13.81)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VTIVanguard Total Stock
RIOTRiot Blockchain
TSLATesla Inc
When determining whether Spruce Biosciences Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Common Stock:
How To Invest In Spruce
Details
Is Spruce Stock a good investment?
Details
What is Spruce Biosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Spruce Biosciences Correlation against competitors.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Spruce Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(84.32)
Revenue Per Share
1.201
Quarterly Revenue Growth
(0.76)
Return On Assets
(0.77)
Return On Equity
(1.68)
Understanding Spruce Biosciences Common requires distinguishing between market price and book value, where the latter reflects Spruce's accounting equity. The concept of intrinsic value—what Spruce Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Spruce Biosciences' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spruce Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY